fda approval cancer by modality - SERP Analysis

https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications

https://www.drugdiscoverytrends.com/4-trends-in-fda-novel-approvals-in-2024/

https://www.nature.com/articles/d41573-025-00001-5

https://www.accc-cancer.org/state-societies/Texas/resources/txsco-resources/fda-oncology-drug-approvals

https://www.onclive.com/view/onclive-s-june-roundup-of-key-fda-approvals-in-oncology

https://www.lgcstandards.com/US/en/Resources/Articles/novel-therapies-approvals-by-fda

https://pubmed.ncbi.nlm.nih.gov/38917371/

https://www.targetedonc.com/view/the-targeted-pulse-the-latest-fda-actions-across-cancer-types-and-exploring-the-efficiency-of-remote-pharmacists-in-community-oncology

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790102

https://cancerprogressreport.aacr.org/progress/cpr23-contents/cpr23-spotlight-on-immunotherapy-pushing-the-frontier-of-cancer-medicine/

https://www.novocure.com/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals

https://www.nature.com/articles/d41573-024-00035-1

https://reflexion.com/press-releases/reflexion-receives-fda-clearance-for-scintix-biology-guided-radiotherapy-cutting-edge-treatment-applicable-for-early-and-late-stage-cancers/

https://aacrjournals.org/cdnews/news/2095/15-Novel-Cancer-Drugs-OK-d-by-FDA-in-2024

https://www.biospace.com/fda/5-novel-fda-approvals-notched-in-2024

https://www.cancerresearch.org/blog/introducing-the-cri-cancer-immunotherapy-insights-impact-report

https://pmc.ncbi.nlm.nih.gov/articles/PMC10416257/

https://www.onclive.com/view/onclive-s-fda-approval-report-the-regulatory-rundown-for-january-2025

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-receives-fda-expanded-access-authorization-landmark

https://www.targetedonc.com/view/the-targeted-pulse-unlock-recent-fda-highlights-in-leukemia-and-prostate-cancer-and-an-interesting-vaccine-gaining-traction-in-triple-negative-breast-cancer

https://www.cancer.gov/news-events/cancer-currents-blog/2015/dinutuximab-neuroblastoma

https://www.researchgate.net/publication/371772181_Trends_in_the_approval_of_cancer_therapies_by_the_FDA_in_the_twenty-first_century

https://drugdiscoveryandbiotech.com/principles-and-concepts/advanced-drug-modalities-part-3-antibody-drug-conjugates-adcs

https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-gavretotm-pralsetinib

https://www.mdpi.com/1424-8247/16/4/614

https://aacrjournals.org/clincancerres/article/28/6/1072/682028/U-S-FDA-Drug-Approvals-for-Breast-Cancer-A-Decade

https://oncodaily.com/insight/10-most-promising-cancer-drugs-2024

https://pharmaphorum.com/oncology/aacr-2025-new-modalities-and-remaining-challenges

https://www.labiotech.eu/trends-news/asco-2025-key-highlights-cancer-therapeutics/

https://www.illumina.com/company/news-center/feature-articles/LP-ASCO.html

https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

https://www.precisionmedicineonline.com/precision-oncology/arteraai-seeks-drive-personalized-prostate-cancer-treatment-decisions-multi

https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer.html

https://www.modality-solutions.com/fda-grants-priority-review-to-agenus-balstilimab-for-cervical-cancer-after-chemotherapy/

https://link.springer.com/10.1007/978-3-031-35529-5_135

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-astellas-xtandir-approved-us-fda-earlier

https://www.patientcareonline.com/view/we-need-to-shift-the-modality-mix-for-colorectal-cancer-screening-says-primary-care-clinician-and-researcher-k-fendrick-md

https://www.fda.gov/drugs/novel-drug-approvals-fda/new-drug-therapy-approvals-2022

https://www.aacr.org/blog/2025/04/03/fda-approvals-in-oncology-january-march-2025/

https://www.cancernetwork.com/view/fda-approves-enzalutamide-xtandi-late-stage-prostate-cancer

https://www.amgen.com/newsroom/press-releases/2024/05/fda-approves-imdelltra-tarlatamabdlle-the-first-and-only-tcell-engager-therapy-for-the-treatment-of-extensivestage-small-cell-lung-cancer

https://news.abbvie.com/2025-05-14-U-S-FDA-Approves-EMRELIS-TM-telisotuzumab-vedotin-tllv-for-Adults-With-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-With-High-c-Met-Protein-Overexpression

https://www.novocure.com/

https://www.keytruda.com/

https://news.llu.edu/patient-care/lluh-first-west-treat-sickle-cell-disease-patient-fda-approved-gene-therapy-lovo-cel

https://www.urotoday.com/video-lectures/mhspc/video/mediaitem/4883-fda-approves-darolutamide-for-metastatic-hormone-sensitive-prostate-cancer-neal-shore.html

https://www.prnewswire.com/news-releases/fda-approves-16-new-cancer-treatments-as-global-cancer-rates-skyrocket-302267613.html

https://www.ajmc.com/view/relacorilant-plus-nab-paclitaxel-improves-outcomes-in-platinum-resistant-ovarian-cancer-brian-slomovitz-md

https://www.stocktitan.net/news/IBRX/immunity-bio-receives-fda-expanded-access-authorization-for-landmark-r7jen8fl8qgp.html

https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/

https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21844

https://www.morningstar.com/news/business-wire/20250602946558/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors

https://www.mayoclinic.org/documents/mc2024-1213pdf/doc-20085755

https://www.curetoday.com/view/targeting-esr1-mutations-early-may-improve-outcomes-in-breast-cancer

https://www.keytruda.com/how-does-keytruda-work/

https://www.sciencedirect.com/science/article/pii/S2772610X2300003X

https://www.oncnursingnews.com/view/peripheral-neuropathy-treatable-with-teliso-v-in-c-met-high-nsclc

https://www.itnonline.com/content/fda-authorizes-ai-platform-breast-cancer-prediction

https://shuttlepharma.com/shuttle-pharmaceuticals-receives-fda-approval-to-proceed-with-phase-ii-clinical-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma/

https://www.biopharmadive.com/news/fda-iovance-til-solid-tumor-cell-therapy/708073/

https://www.astellas.com/en/news/29291

https://www.ajmc.com/view/fda-approves-trodelvy-for-metastatic-triplenegative-breast-cancer

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1184472/full

https://finance.yahoo.com/news/immunitybio-receives-fda-expanded-access-130000203.html

https://www.tandfonline.com/doi/pdf/10.4161/cc.3.8.1023

https://cdn.mdedge.com/files/s3fs-public/issues/articles/70173_main_4.pdf

https://www.modality-solutions.com/jazz-pharmaceuticals-announces-u-s-fda-approval-of-rylaze-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma/

https://www.zs.com/insights/oncology-antibody-drug-conjugates-revolution

https://www.businesswire.com/news/home/20250602946558/en/ImmunityBio-Receives-FDA-Expanded-Access-Authorization-for-Landmark-Treatment-of-Lymphopenia-With-ANKTIVA-the-Cancer-BioShield-Platform-in-Patients-With-Solid-Tumors

https://www.personalizedmedonc.com/all-articles/688:fda-approves-opdivo-nivolumab-for-the-treatment-of-patients-with-previously-treated-metastatic-squamous-non-small-cell-lung-cancer-ito

https://www.gsk.com/en-gb/media/press-releases/zejula-niraparib-is-the-first-and-only-once-daily-parp-inhibitor-fda-approved-as-a-first-line-monotherapy-maintenance-treatment-for-women-with-advanced-ovarian-cancer/

https://www.spandidos-publications.com/10.3892/or.2022.8405

https://ir.blueprintmedicines.com/news-releases/news-release-details/fda-approves-ayvakitr-avapritinib-first-and-only-treatment

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35122

https://www.mdpi.com/2072-6694/16/16/2777

https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html

https://www.drugs.com/history/ontruzant.html

https://www.sciencedirect.com/science/article/pii/S0960977624001619

https://www.empr.com/charts/fda-approved-breast-cancer-treatments/

https://www.researchgate.net/figure/NMPA-and-FDA-approved-targeted-drugs-by-modality-2023-a-Small-molecules-and_fig1_378353342

https://reflexion.com/press-releases/fda-clearance-brings-reflexion-closer-to-expanding/

https://www.cancernetwork.com/view/vismodegib-granted-fda-approval-treatment-basal-cell-carcinoma

https://www.gsk.com/en-gb/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/

https://www.uspharmacist.com/article/trends-in-fdaapproved-cancer-therapies?utm_source=TrendMD&utm_medium=cpc&utm_campaign=US_Pharmacist_TrendMD_1

https://news.bms.com/news/details/2015/FDA-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Previously-Treated-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer/default.aspx

https://www.iovance.com/

https://www.regeneron.com/medicines/our-medicines/us-approved

https://www.bms.com/

https://www.oncologypipeline.com/apexonco/asco-2025-amgen-gets-one-over-zai-lab

https://firstwordpharma.com/story/5968403

https://www.pfizer.com/

https://www.pharmalive.com/car-t-therapies-need-to-overcome-current-limitations-to-unlock-promising-treatment-possibilities-for-solid-tumors/

https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103792s5175lbl.pdf

https://my.clevelandclinic.org/health/treatments/15840-transcutaneous-electrical-nerve-stimulation-tens

https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625

https://pubs.acs.org/doi/10.1021/acsami.5c02984

https://www.patientcareonline.com/view/mark-fendrick-md-is-passionate-about-colorectal-cancer-screening-and-doing-it-right

https://senomedical.com/newsroom/press-releases/newsroom-press-releases-2021-fda-approves-seno-medicals-ground-breaking-breast-cancer-diagnostic-technology